|
|
||||||||||||||
|
|
|||||||||||||||
Therapeutics |
Clinical impact ratings IM/Ambulatory care






Haematology 





Endrocrine 





Key Words: phthalic acids vascular diseases diabetes mellitus (type 2)
| The first 150 words of the full text of this article appear below. |
METHODS
Design:
randomised placebo controlled trial (Drug Evaluation in Atherosclerotic Vascular Disease in Diabetics [DAVID] study).
Allocation:
concealed.*
Blinding:
blinded (clinicians, patients, data collectors, outcome assessors, and data safety and monitoring committee).*
Follow up period:
24 months.
Setting:
86 centres in Italy.
Patients:
1209 patients who were 4075 years of age (mean age 64 y, 73% men) with type 2 diabetes for
5 years and PAD (
2 of intermittent claudication for >2 mo, loss of posterior tibial pulse in the foot, ankle/arm pressure ratio <0.90 or >1.30 in the posterior or anterior tibial artery of the foot, amputation or reconstructive surgery in patients with previous intermittent claudication, or angioplasty). Exclusion criteria included myocardial infarction (MI), stroke, or unstable angina in the previous 6 months; severe neurological or mental deficits; severe comorbid conditions that would limit life expectancy to <2 years; serum creatinine >2.0 mg/dl (176 µmol/l); pregnancy; severe uncontrolled hypertension;
Donald A Smith, MD, MPH
Mount Sinai School of Medicine, New York, New York, USA
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |